February 10, 2020
The Japanese unit of Janssen and Nippon Shinyaku have sealed an agreement to copromote the Johnson & Johnson company’s prostate cancer treatment Zytiga (abiraterone) in Japan, the two partners said on February 7, a year after they formed a similar...read more